Evaluation of HIV-1 Immunogen, an Immunologic Modifier, Administered to Patients Infected With HIV Having 300 to 549 × 106/L CD4 Cell Counts
A Randomized Controlled Trial
- James O. Kahn, MD;
- Deborah Weng Cherng, MS;
- Kenneth Mayer, MD;
- Henry Murray, MD;
- Stephen Lagakos, PhD;
- for the 806 Investigator Team
- Author Affiliations: Positive Health Program, University of California, San Francisco and San Francisco General Hospital, San Francisco, Calif (Dr Kahn); Harvard School of Public Health, Boston, Mass (Ms Cherng and Dr Lagakos); Memorial Hospital of Rhode Island, Pawtucket, and Brown University, Providence, RI (Dr Mayer); and Cornell University Henry Weill Medical College, New York, NY (Dr Murray).
Abstract
Context Despite enormous improvements achieved through the use of antiretroviral therapies (ARTs), the risk for eventual human immunodeficiency virus (HIV) disease progression remains high. Agents that enhance the immunologic mechanism for viral recognition might reduce disease progression.
Objective To determine whether the addition of HIV-1 Immunogen would confer added clinical efficacy to that achievable by ARTs.
Design and Setting Multicenter, double-blind, placebo-controlled, randomized trial beginning March 1996 and ending May 1999 conducted at 77 centers in the United States providing primary care or referral care for persons infected with HIV.
Patients Adults infected with HIV who have baseline CD4 cell counts between 300 × 106/L and 549 × 106/L without prior acquired immunodeficiency syndrome–defining conditions receiving stable ART (or no therapy) were screened and 2527 were randomized.
Interventions Ten units of HIV-1 Immunogen, derived from a Zairian HIV isolate, inactivated and formulated with incomplete Freund adjuvant, was administered intramuscularly every 12 weeks. The placebo was incomplete Freund adjuvant. Changes in ARTs were allowed.
Main Outcome Measures HIV progression-free survival; secondary end points included overall survival, changes in HIV RNA, CD4 cell counts, CD4 percentage, body weight, and immunogenicity.
Results The overall event rate was 1.8 per 100 person-years of follow-up. Fifty-three subjects developed clinical progression in each treatment group (relative risk [RR], 0.97; 95% confidence interval [CI], 0.66-1.42; P = .89). There were 19 and 23 deaths in the placebo and HIV-1 Immunogen groups, respectively (RR, 0.81; 95% CI, 0.44-1.48; P = .49). There were no statistically significant differences between the groups with respect to changes in HIV RNA (P = .59), CD4 percentage (P = .63), or body weight (P = .89). Subjects in the HIV-1 Immunogen group had an increase in average CD4 cell count of approximately 10 × 106/L greater than the placebo group (P = .02).
Conclusion HIV-1 Immunogen with unrestricted ART failed to demonstrate an increase in HIV progression-free survival.
